<DOC>
	<DOC>NCT01103609</DOC>
	<brief_summary>The purpose of this study is to determine whether AZD1656 will affect the Pharmacokinetics and Pharmacodynamics of Warfarin in T2DM patients.</brief_summary>
	<brief_title>Investigate the Effect of AZD1656 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Type 2 Diabetes Mellitus (T2DM) Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Clinical diagnosis of T2DM treated with at least 1000 mg metformin as a single treatment or in combination with one other oral antidiabetics for at least 2 months prior to screening. Doses of antidiabetic treatment stable for at least 1 month Fasting plasma glucose (FPG) at screening in the range of 6.0 to 15.0 mmol/L (108 to 270 mg/dL) and FPG in the range of 7.5 to 13.0 mmol/L (135 to 234 mg/dL) on Day 1 Haemoglobin (Hb) A1c &gt;6.5% at screening Use of drugs with anticoagulant effects 3 weeks prior to first warfarin dosing Use of amiodarone within 3 months prior to screening and the use of potent CYP450 inhibitors Previous treatment with warfarin on clinical indication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Type 2</keyword>
	<keyword>Warfarin</keyword>
	<keyword>drug-drug interaction</keyword>
</DOC>